Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman B. Fitchett D, et al. Among authors: pfarr e. Circulation. 2019 Mar 12;139(11):1384-1395. doi: 10.1161/CIRCULATIONAHA.118.037778. Circulation. 2019. PMID: 30586757 Free PMC article. Clinical Trial.
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.
Zannad F, Ferreira JP, Pocock SJ, Zeller C, Anker SD, Butler J, Filippatos G, Hauske SJ, Brueckmann M, Pfarr E, Schnee J, Wanner C, Packer M. Zannad F, et al. Among authors: pfarr e. Circulation. 2021 Jan 26;143(4):310-321. doi: 10.1161/CIRCULATIONAHA.120.051685. Epub 2020 Oct 23. Circulation. 2021. PMID: 33095032 Free PMC article.
Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
Lam CSP, Ferreira JP, Pfarr E, Sim D, Tsutsui H, Anker SD, Butler J, Filippatos G, Pocock SJ, Sattar N, Verma S, Brueckmann M, Schnee J, Cotton D, Zannad F, Packer M. Lam CSP, et al. Among authors: pfarr e. Eur Heart J. 2021 Nov 14;42(43):4442-4451. doi: 10.1093/eurheartj/ehab360. Eur Heart J. 2021. PMID: 34184057 Free PMC article. Clinical Trial.
Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.
Anker SD, Ponikowski P, Wanner C, Pfarr E, Hauske S, Peil B, Salsali A, Ritter I, Koitka-Weber A, Brueckmann M, Lindenfeld J, Abraham WT; EMPERIAL Investigators and National Coordinators. Anker SD, et al. Among authors: pfarr e. Circulation. 2021 Oct 12;144(15):1265-1267. doi: 10.1161/CIRCULATIONAHA.121.054669. Epub 2021 Aug 16. Circulation. 2021. PMID: 34397263 Free article. No abstract available.
Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced.
Anker SD, Khan MS, Butler J, Ofstad AP, Peil B, Pfarr E, Doehner W, Sattar N, Coats AJS, Filippatos G, Ferreira JP, Zannad F, Pocock S, Packer M. Anker SD, et al. Among authors: pfarr e. Eur J Heart Fail. 2023 Jan;25(1):117-127. doi: 10.1002/ejhf.2728. Epub 2022 Nov 24. Eur J Heart Fail. 2023. PMID: 36325584 Free PMC article. Clinical Trial.
Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled.
Verma S, Dhingra NK, Butler J, Anker SD, Pedro Ferreira J, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Pfarr E, Nordaby M, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Pooled Trial Committees and Investigators. Verma S, et al. Among authors: pfarr e. Circulation. 2023 Jan 3;147(1):101-104. doi: 10.1161/CIRCULATIONAHA.122.062644. Epub 2022 Nov 7. Circulation. 2023. PMID: 36342827 No abstract available.
42 results